<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125908">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01702974</url>
  </required_header>
  <id_info>
    <org_study_id>IREHIV-2012</org_study_id>
    <nct_id>NCT01702974</nct_id>
  </id_info>
  <brief_title>Immune Reconstitution in HIV Disease (IREHIV)</brief_title>
  <acronym>IREHIV</acronym>
  <official_title>Immune Reconstitution in HIV Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Ethiopia: Food, Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim with this study is to provide immunotherapy with vitamin D and phenylbutyrate to
      treatment-naive HIV infected patients to induce important antimicrobial defence mechanisms
      and decreased inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HIV viral load</measure>
    <time_frame>0 (baseline) compared to 16 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma HIV viral load will be used to monitor efficacy of vitamin D and phenylbutyrate treatment among treatment-na√Øve HIV patients at the time of diagnosis (time point 0) and at 4, 8, 16 and 24 weeks after initiation of antimicrobial treatment with vitamin D and phenylbutyrate. The primary endpoint will be assessed at 16 weeks compared to baseline (time point 0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical secondary endpoints</measure>
    <time_frame>0, 4, 8, 16, 24 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall clinical symptoms.
Body mass index (BMI).
Mid upper arm circumference (MUAC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory secondary endpoints</measure>
    <time_frame>0, 4, 8, 16, 24 weeks.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HIV viral load (0, 4, 8, 24 weeks).
Peripheral CD4/CD8 T cell counts.
Plasma levels of vitamin D, LL-37, sCD14, LPS, 16S RNA and cytokine/chemokine profiles.
Calprotectin in feces.
Inflammation and microbial translocation in colon punch biopsies (0 and 16 weeks).
Functional studies of immune cells (PBMCs).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Interim analysis</measure>
    <safety_issue>Yes</safety_issue>
    <description>An interim analysis will be performed after approx. 75-100 patients have been included into the study.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)</intervention_name>
    <description>Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.</description>
    <arm_group_label>Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.</description>
    <arm_group_label>Placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients &gt;18 years not subjected to HAART.

        HIV-1 infected patients with CD4 T cells counts &gt;200 cells/ml.

        Detectable plasma viral loads &gt;5000 copies/ml.

        Exclusion Criteria:

        Patients on HAART or other antimicrobial drugs (including bactrim).

        Antimicrobial drug treatment in the past month.

        Patients with medical contra-indication for biopsy such as bleeding tendencies.

        Hypercalcaemia (serum calcium &gt; 2.6 mmol/L) identified at baseline.

        Pregnant and breast feeding women.

        Any known liver or kidney function abnormality, malignancy or patients treated with
        cardiac glycosides.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Brighenti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wondwossen Amogne, MD</last_name>
    <phone>251-911406179</phone>
    <email>wonamogne@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Endale Kassa, MD</last_name>
    <phone>251-911228562</phone>
    <email>endalekassalulu@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine</name>
      <address>
        <city>Addis Ababa</city>
        <state>Lideta sub city</state>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wondwossen Amogne, MD</last_name>
      <phone>251-911406179</phone>
      <email>wonamogne@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Wondwossen Amogne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Endale Kassa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 8, 2012</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Susanna Brighenti</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>sodium phenylbutyrate</keyword>
  <keyword>antimicrobial peptides</keyword>
  <keyword>immune response</keyword>
  <keyword>inflammation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
